Tuberculosis clinical units improve contact tracing

Int J Tuberc Lung Dis. 2016 Dec 1;20(12):1572-1579. doi: 10.5588/ijtld.16.0147.

Abstract

Introduction: The Barcelona Tuberculosis Programme was established in 1987, and in 2007 five tuberculosis (TB) clinical units were created to improve the follow-up of cases and contacts. This included the designation of a nurse for case management.

Objective: To assess the impact of the TB clinical units on the screening programme for TB contacts.

Methods: Before-after population-based study before (2003-2007) and after (2008-2013) the creation of the clinical units. To determine which factors were related to contact tracing, we fitted a multivariate logistic regression model to estimate odds ratios (OR) with their 95% confidence intervals (CIs).

Results: Following the creation of the clinical units, the proportion of prescriptions for latent tuberculous infection among contacts in the clinical units increased from 40.7% to 57.4% (P < 0.001), and treatment adherence from 75.9% to 80.3% (P = 0.035). One factor associated with contact tracing was receiving care after the creation of the clinical units (2008-2013) (OR 1.2, 95%CI 1.0-1.3). During the second period, receiving care outside the clinical units reduced the probability of contact tracing (OR 0.7, 95%CI 0.5-0.9).

Conclusion: The creation of the TB clinical units represents an organisational improvement for the study and management of contacts of patients with TB.

Publication types

  • Observational Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antitubercular Agents / administration & dosage*
  • Child
  • Child, Preschool
  • Contact Tracing*
  • Female
  • Follow-Up Studies
  • Humans
  • Incidence
  • Infant
  • Infant, Newborn
  • Isoniazid / administration & dosage
  • Latent Tuberculosis / epidemiology*
  • Latent Tuberculosis / prevention & control
  • Male
  • Middle Aged
  • Patient Compliance
  • Risk Factors
  • Spain / epidemiology
  • Young Adult

Substances

  • Antitubercular Agents
  • Isoniazid